Prexasertib

DRUG15 trials

Sponsors

Eli Lilly and Company, M.D. Anderson Cancer Center, Children's Oncology Group, Geoffrey Shapiro, MD, PhD, Dana-Farber Cancer Institute

Conditions

Acute Myeloid LeukemiaAdvanced CancerAnal Squamous Cell CarcinomaBrain CancerBrain TumorBrain Tumor, PediatricBrain Tumor, RecurrentBrain Tumor, Refractory

Phase 1

A Phase 1 Study in Participants With Advanced Cancer

CompletedNCT01115790

Eli Lilly and CompanyAdvanced Cancer, Anal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung +3

Start: 2010-02-28End: 2016-01-31Updated: 2016-05-10

A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer

CompletedNCT02124148

Eli Lilly and CompanyBreast Cancer, Colorectal Neoplasms, Neoplasm Metastasis

Start: 2014-06-18End: 2020-02-13Updated: 2020-04-01

A Study of Prexasertib (LY2606368) in Japanese Participants With Advanced Cancers

CompletedNCT02514603

Eli Lilly and CompanyNeoplasm

Start: 2015-10-31End: 2017-04-10Updated: 2017-05-22

A Study of Prexasertib (LY2606368) With Chemotherapy and Radiation in Participants With Head and Neck Cancer

CompletedNCT02555644

Eli Lilly and CompanyHead and Neck Neoplasms

Start: 2016-02-24End: 2019-01-14Target: 70Updated: 2019-02-15

Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

CompletedNCT02649764

M.D. Anderson Cancer CenterChronic Myelomonocytic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent High Risk Myelodysplastic Syndrome +2

Start: 2016-05-04End: 2022-07-12Updated: 2023-10-04

A Study of Prexasertib (LY2606368) in Participants With Advanced Cancer

CompletedNCT02778126

Eli Lilly and CompanyAdvanced Cancer

Start: 2016-09-22End: 2017-07-27Updated: 2019-08-01

Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

CompletedNCT02808650

Children's Oncology GroupChildhood Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Primary Central Nervous System Neoplasm +2

Start: 2017-02-27End: 2021-03-31Updated: 2023-12-20

A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer

CompletedNCT02860780

Eli Lilly and CompanyAdvanced Cancer, Colorectal Cancer, Metastatic Cancer +1

Start: 2016-08-10End: 2017-05-15Updated: 2018-12-14

Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors

CompletedNCT03057145

Geoffrey Shapiro, MD, PhDSolid Tumor

Start: 2017-03-10End: 2021-06-09Updated: 2021-09-02

A Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid Tumors

CompletedNCT03495323

Dana-Farber Cancer InstituteCancer

Start: 2018-05-16End: 2021-02-01Updated: 2021-04-15

Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial

TerminatedNCT03735446

Dana-Farber Cancer InstituteAcute Myeloid Leukemia, Myelodysplastic Syndromes

Start: 2019-01-18End: 2019-03-29Updated: 2019-06-12

Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors

CompletedNCT04023669

St. Jude Children's Research HospitalBrain Cancer, Brain Tumor, Brain Tumor, Pediatric +10

Start: 2019-08-08End: 2025-01-13Updated: 2025-02-07

A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and Rhabdomyosarcoma

CompletedNCT04095221

Memorial Sloan Kettering Cancer CenterDesmoplastic Small Round Cell Tumor, Rhabdomyosarcoma

Start: 2019-09-17End: 2025-02-18Updated: 2025-02-20

Phase 2

A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer

CompletedNCT02735980

Eli Lilly and CompanySmall Cell Lung Cancer

Start: 2016-05-11End: 2019-02-12Updated: 2020-03-17

A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer

CompletedNCT03414047

Eli Lilly and CompanyOvarian Cancer

Start: 2018-04-10End: 2020-10-03Updated: 2022-08-19

Related Papers

MDB-65. RESULTS FROM THE SJ-ELIOT PHASE 1 CLINICAL TRIAL EVALUATING PREXASERTIB (LY2606368) IN COMBINATION WITH CYCLOPHOSPHAMIDE OR GEMCITABINE FOR CHILDREN AND ADOLESCENTS WITH REFRACTORY OR RECURRENT MEDULLOBLASTOMA

Neuro-Oncology2024-06-182 citations

Abstract B012: Validation of the OncoSignature assay, an ACR-368-tailored response-predictive quantitative multiplexed immunofluorescent assay for prediction of sensitivity to the CHK1/2 inhibitor ACR-368 in individual patients with cancer

Molecular Cancer Therapeutics2023-12-01

A Phase 2 study of prexasertib (LY2606368) in platinum resistant or refractory recurrent ovarian cancer.

2022-09-3048 citations

A phase I/II study of prexasertib in combination with irinotecan in patients with relapsed/refractory desmoplastic small round cell tumor and rhabdomyosarcoma.

Journal of Clinical Oncology2022-06-0112 citations

A Phase 1b Trial of Prexasertib in Combination with Standard-of-Care Agents in Advanced or Metastatic Cancer.

2021-09-2422 citations

Highlights from Recent Cancer Literature

Cancer Research2021-04-01

Immune modulating activity of the CHK1 inhibitor prexasertib and anti-PD-L1 antibody LY3300054 in patients with high-grade serous ovarian cancer and other solid tumors.

2021-03-2024 citations

Abstract 3031: Characterization of gemcitabine triphosphate formation in mice to aid in the development of a translational tumor model

Cancer Research2020-08-15

CHK1/2 Inhibitor Prexasertib Suppresses NOTCH Signaling and Enhances Cytotoxicity of Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma

Molecular Cancer Therapeutics2020-05-0540 citations

Abstract 1761: Inhibition of PI3K/AKT/mTOR signaling by a dual PI3K/mTOR inhibitor (LY3023414) potentiates the antitumor efficacy of the Chk1 inhibitor prexasertib (LY2606368) in models of human high-grade serous ovarian cancer (HGSOC)

Cancer Research2019-07-013 citations

Abstract 3508: Combination of the Chk1 inhibitor (prexasertib) with a PI3K/mTOR inhibitor (LY3023414) induces synergistic anti-tumor activity in triple negative breast cancer (TNBC) models

Cancer Research2019-07-013 citations

Abstract 1761: Inhibition of PI3K/AKT/mTOR signaling by a dual PI3K/mTOR inhibitor (LY3023414) potentiates the antitumor efficacy of the Chk1 inhibitor prexasertib (LY2606368) in models of human high-grade serous ovarian cancer (HGSOC)

Molecular and Cellular Biology / Genetics2019-07-011 citations

Abstract 3508: Combination of the Chk1 inhibitor (prexasertib) with a PI3K/mTOR inhibitor (LY3023414) induces synergistic anti-tumor activity in triple negative breast cancer (TNBC) models

Molecular and Cellular Biology / Genetics2019-07-01

A phase Ib study of prexasertib, a checkpoint kinase (CHK1) inhibitor, and LY3023414, a dual inhibitor of class I phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR) in patients with advanced solid tumors.

Journal of Clinical Oncology2019-05-204 citations

Abstract A42: Prexasertib (LY2606368) is highly active as a monotherapy or in combination with chemotherapy in preclinical models of pediatric bone and soft tissue sarcoma

Cancer Research2018-10-01

A phase 1b dose-escalation study of prexasertib, a checkpoint kinase 1 (CHK1) inhibitor, in combination with cisplatin in patients with advanced cancer.

Journal of Clinical Oncology2018-05-205 citations

Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma

Clinical Cancer Research2018-04-1185 citations

Abstract A108: DNA damage repair targeting upregulates PD-L1 level and potentiates the effect of PD-L1 blockade in small cell lung cancer

Molecular Cancer Therapeutics2018-01-01

Abstract 1778: A clinical genomic biomarker study of the CHK1 inhibitor prexasertib in advanced head and neck squamous cancer and squamous cell carcinoma of the anus

Cancer Research2017-07-011 citations

Combining Chk1/2 Inhibition with Cetuximab and Radiation Enhances <i>In Vitro</i> and <i>In Vivo</i> Cytotoxicity in Head and Neck Squamous Cell Carcinoma

Molecular Cancer Therapeutics2017-01-3054 citations

3 more papers not shown